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times Colombian GDP per capita) bendamustine is a cost effective alternative to 
fludarabine.
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Objectives: To determine the cost-effectiveness of cabazitaxel, based mainly on 
the TROPIC trial in 2nd line treatment of mHRPC relative to the standard of care 
at the time of launch of the drug. MethOds: A Markov model was developed to 
comprise set of different health states each associated with costs, effects and prob-
abilities of moving to other state. In simulation, a cohort of defined patients are run 
through the model during the time period of choice, it’s assumed that transitions 
between states only occurs at equidistant time-points and the interval is called a 
cycle. Because of the relatively short survival time of mHRPC patients, cycle length 
in the model was set at 3 weeks, corresponding to the length of one chemotherapy 
administration cycle. Transition rates between different states representing mHRPC 
disease progression were estimated based on progression of disease and survival 
rates from the TROPIC trial. Results: According to the approved labeling in Turkey, 
a subgroup of patients with ECOG PS 0-1 and measurable disease at baseline was 
identified on TROPIC results with a secondary analysis. The result of this analysis 
shows a similar OS outcomes with decreased death rates. Cabazitaxel was cost-
effective compared mitoxantrone with cost per LYG of TRY66,862 given the thresh-
old of TRY68,409 per LYG for the subgroup of the patients at ECOG PS 0-1 and with 
measurable disease at baseline. Although there has been no formal threshold for 
the cost-effectiveness ratio in Turkey, a threshold of TRY68,409 per LY gained was 
assumed based on WHO-CHOICE criteria (3xGDP percapita). cOnclusiOns: It is 
difficult for the results of the analysis to be interpreted because there is no official 
cost-effectiveness threshold in Turkey. However, from the WHO perspective; results 
showed that cabazitaxel is a cost-effective treatment with all ICER values compared 
to mitoxantrone, below TRY68,409.
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Objectives: Gene expression profiling (GEP) and expanded immunohistochemis-
try (IHC) tests aim to improve decision-making relating to adjuvant chemotherapy 
for women with early breast cancer (EBC) at intermediate or high risk of recurrence 
following primary surgery. MethOds: A probabilistic model was developed to 
evaluate the cost effectiveness of treatment guided using the OncotypeDx and 
IHC4 tests compared with current clinical practice in England and Wales. Analysis 
was undertaken for women with oestrogen receptor positive (ER+), lymph node 
negative (LN–), and HER2– EBC from a NHS perspective. In the comparator arm, 
cancer registry data was used to inform the proportion of patients receiving chem-
otherapy under current practice. In the intervention arm (new test in addition to 
current practice) patients were classified into different risk categories based on the 
result of the new test. The likelihood of receiving chemotherapy was dependent on 
this classification. The natural history of breast cancer was then simulated using 
a state transition Markov model, taking into account the reduction in the risk of 
recurrence associated with chemotherapy. Results: The economic analysis sug-
gested that treatment guided using IHC4 has the most potential to be cost-effective 
at a threshold of £20,000 per QALY gained; however the evidence base to support 
IHC4 needs further research to confirm the analytical validity of the test and to 
clarifiy the cost of the test in clinical practice. OncotypeDX has a more robust 
evidence base, but further evidence on the impact on decision making in the UK 
and the predictive ability of the test in an ER+, LN-, HER- population receiving 
current treatment regimens is needed to confirm whether or not it constitutes 
a cost-effective option in the UK. cOnclusiOns: GEP and IHC tests have the 
potential to constitute a cost effective option in the UK, but further research is 
needed to confirm this finding.
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Objectives: To perform comparative pharmacoeconomic analysis of aprepitant 
plus standard antiemetic therapy – 5-hydroxytriptamine-3 antagonist and cor-
ticosteroid - for prevention chemotherapy-induced nausea and vomiting (CINV) 
versus standard antiemetic therapy. MethOds: Analysis of the published clinical 
trials was conducted to evaluate comparative efficacy and safety of three-drug 
combination. Cost-effectiveness analyses was performed. Direct medical costs of 
treatment with studied drugs were considering for each option: cost for 1-cycle and 
6-cycle cancer chemotherapy (CCT) with highly emetogenic drugs and for 1-cycle 
and 4-cycle CCT with moderately emetogenic drugs for 1 patient. The calculation of 
costs was based on drugs’ prices from the List of Vital and Essential Drugs in Moscow 
region. The incremental cost-effectiveness ratio (ICER) was estimated. One-way 
sensitivity analysis was made. Results: According to published trials the using 
aprepitant plus standard antiemetic therapy in patients receiving highly and mod-
erately emetogenic chemotherapy was associated with a significant improvement 
in control of CINV. The ICER was 593.7 USD per 1-cycle and 2906.6 USD per 6-cycle 
CCT with highly emetogenic drugs for 1 patient. The ICER was 852.7 USD per 1-cycle 
and 4570.1 USD per 4-cycle CCT with moderately emetogenic therapy. The one-way 
sensitivity analysis showed that the results are more sensitive to the variations of 
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Objectives: Treatment options for chemotherapy-refractory liver metastases result-
ing from colorectal cancer are limited. The safety and efficacy of SIRT using resin 
yttrium-90 microspheres was studied in this population. The objective of this analysis 
was to assess the cost-effectiveness of SIRT compared to best supportive care (BSC) 
from the perspective of the UK NHS. MethOds: A state-transition model was con-
structed, based on survival curves from a retrospective cohort study of yttrium-90 
resin microspheres (SIR-Spheres; Sirtex, Sydney, Australia) vs. BSC in chemotherapy-
refractory mCRC. The model included costs for treatment acquisition, pre-treatment 
work-up and delivery of microspheres, and chemotherapy received in addition to, 
instead of, or after, SIRT. In addition, costs of managing AEs and a cost of death were 
included. Costs were microcosted using NHS reference costs and the British National 
Formulary 64. Utility data were taken from a recent NICE economic evaluation in 
metastatic colorectal cancer. Results: The results showed an increase in survival 
for patients receiving SIRT compared to BSC (2.09 vs. 0.97 years), with a correspond-
ing increase in quality adjusted life years (1.50 vs 0.69). The associated costs were 
£35,487 vs.£12,730 for SIRT and BSC, respectively. The additional costs were due to 
the SIRT treatment and the cost associated with extension to life. The cost per QALY 
was £28,216 (cost per life year £20,323). The results were robust to alternative assump-
tions tested in scenario analyses; survival functions, utilities or the time spent pre- 
and post-progression. However, one-way sensitivity analysis showed results were 
most sensitive to the parameters for the survival functions. Data shown here were 
also consistent with published clinical studies. cOnclusiOns: The analysis dem-
onstrates that SIRT using resin yttrium-90 microspheres has the potential of being a 
cost-effective option in the treatment of patients with chemotherapy-refractory liver 
metastases resulting from colorectal cancer.
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Objectives: To perform comparative pharmacoeconomic analysis of concomi-
tant, adjuvant and second-line intravenous temozolomide (ITMZ) for the treat-
ment of newly diagnosed glioblastoma multiforme versus initial radiotherapy and 
second-line therapy with ITMZ. MethOds: Analysis of the published clinical trials 
was conducted to evaluate comparative efficacy and safety of the studied therapy 
options. Direct medical costs included drug therapy and hospital treatment. All 
prices were for Moscow region, year 2013. Expected difference in direct medical costs 
was calculated in Excel based model. For the cost-effectiveness analysis, survival 
was expressed as 2.5 years restricted mean estimates from EORTC-NCIC study. 
The incremental cost-effectiveness ratio (ICER) was estimated. One-way sensitivity 
analysis was made. Results: According to published trials the treatment of newly 
diagnosed glioblastoma multiforme with ITMZ was associated with a significant 
improvement in overall survival. The difference in 2.5 years restricted mean survival 
between the treatment arms was 0.25 life-years and the ICER was 76,982.6 USD per 
life-year. The one-way sensitivity analysis showed that the results are more sensi-
tive to the variations of key model parameter, such as price of ITMZ. cOnclusiOns: 
The concomitant, adjuvant and second-line ITMZ was more effective and economi-
cally justified treatment option for patients with newly diagnosed glioblastoma 
multiforme.
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Objectives: To determine the cost-effectiveness of bendamustine versus 
fludarabine for first line treatment of CLL in Colombia. MethOds: An eco-
nomic model was constructed from the Colombian health system perspective, 
with a 25-year (lifetime) horizon and a discount rate of 3%. The model included 
three health states, progression-free (PF), progressive disease (PD), and death. 
Clinical inputs (Kaplan-Meier curves, response rates, hazard ratios (HRs) and 
adverse event (AE) rates) were from a phase 3 trial comparing bendamustine and 
chlorambucil, and from a network meta-analysis. Resource use data were from 
interviews with three Colombian hematologists treating CLL. Resource use for 
PF patients was weighted based on treatment response. Unit costs were from ISS 
and SISPRO report and were expressed in 2013 Colombian Pesos. Univariate and 
probabilistic sensitivity analyses were conducted to determine the key drivers of 
cost-effectiveness, and the uncertainty around the results, respectively. Results: 
The total lifetime costs for bendamustine and fludarabine were $61,982,845 and 
$20,432,209, respectively. Bendamustine patients accrued more LYs (7.52 vs. 
6.50), QALYs (5.61 vs. 4.60), and PF LYs (3.09 vs. 1.14) compared to fludarabine 
patients. The ICERs were $40,530,919 (cost per LY), $41,117,127 (cost per QALY) and 
$21,264,817 (cost per PF LY). Univariate sensitivity analysis revealed the cost per 
LY ICER was most sensitive to progression-free survival and overall survival HRs 
for bendamustine vs. fludarabine, the number of treatment cycles, and the cost 
of bendamustine. Probabilistic sensitivity analysis with 1,000 iterations predicted 
bendamustine had a 71% chance of being cost-effective, compared to fludarabine, 
at a willingness to pay (WTP) of $59M per LY, rising to a plateau of about 80% 
from a WTP of $80M and greater. cOnclusiOns: At current WTP of $59M (three 
